Clinical Trial: Phase IIB Neoadjuvant Enzalutamide (ZT) Plus Taxol for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer (AR+ TNBC)

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional




Official Title: A Phase IIB Study of Neoadjuvant Enzalutamide (ZT) Regimen Therapy in Combination With Weekly Paclitaxel for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer

Brief Summary: The goal of this clinical research study is to learn if a combination of enzalutamide and paclitaxel can help to control triple-negative breast cancer (TNBC) by shrinking the tumors in the breast and/or lymph nodes before they are surgically removed. The safety of this treatment combination will also be studied.